Eli Shalenberg
New York, NYNPI 1013234202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,636 of the $6,721 with a category attached, or 83.9%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,536 and has fallen 99.3% since, to $18 in 2025.
Across 302 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$801
- Otsuka America Pharmaceutical, Inc.$619
- Takeda Pharmaceuticals U.S.A., Inc.$545
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377
- plus $2K from 15 others
Across 72 payments — averaging $1138.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vivus LLC$46K
- AbbVie$20K
- Vanda Pharmaceuticals Inc.$11K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Sunovion Pharmaceuticals Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $824 from 1 others
What the payments were for
- Travel & lodging$84113%
- Food & beverage$5,63684%
- Education$2444%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 18 | $1,371 |
| AbbVie(2 entities) | 74 | $1,155 |
| Teva Pharmaceuticals USA, Inc. | 38 | $801 |
| Otsuka America Pharmaceutical, Inc. | 33 | $619 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $545 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $377 |
| Lundbeck LLC | 19 | $338 |
| Indivior Inc. | 14 | $287 |
| Jazz Pharmaceuticals Inc. | 10 | $214 |
| Eisai Inc. | 8 | $171 |
| Vanda Pharmaceuticals Inc. | 7 | $156 |
| Ironshore Pharmaceuticals Inc. | 5 | $113 |
| Alkermes, Inc. | 5 | $102 |
| Merck | 6 | $97 |
| Shire North American Group Inc | 5 | $96 |
| Adlon Therapeutics L.p. | 6 | $89 |
| Validus Pharmaceuticals LLC | 4 | $58 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Biogen | 2 | $44 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$133
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 55 | $145,077 |
| Invega TrinzaPaliperidone Palmitate | 14 | $118,655 |
| Abilify MaintenaAripiprazole | 28 | $70,734 |
| Risperdal ConstaRisperidone Microspheres | 22 | $23,916 |
| Haloperidol Decanoate | 80 | $4,639 |
| Fluphenazine Hcl | 25 | $4,336 |
| Clozapine | 36 | $3,238 |
| Fluphenazine Decanoate | 45 | $2,750 |
| Olanzapine | 57 | $1,359 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $1,336 |
| Quetiapine Fumarate | 38 | $458 |
| Benztropine Mesylate | 35 | $405 |
| Valproic AcidValproic Acid (As Sodium Salt) | 14 | $403 |
| Trazodone Hcl | 12 | $54 |
| Sertraline Hcl | 18 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $619 | $70,73428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.